Latest News-CLARITY PHARMACEUTICALS Mediaroom_Page

US based COBRA diagnostic prostate cancer trial reaches recruitment target

SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2023-02-09 22:03 3188

IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer

SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights * Clarity's fifth successful Investigational N...

2022-11-21 22:04 4449

First patient treated in Clarity's therapeutic prostate cancer trial

Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic ph...

2022-10-07 21:06 2551

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

SYDNEY, Sept. 5, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical st...

2022-09-05 21:09 3374

Clarity advances to cohort 3 of the CL04 trial of SARTATE™ in paediatric neuroblastoma

Highlights * Cohort 2 completed in participants with neuroblastoma who received therapy with67Cu...

2022-08-23 21:04 3724

Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial

SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...

2022-07-20 21:06 2219

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Highlights * IND approval received for SAR-Bombesin product, enabling a Phase II "SABRE" imaging...

2022-06-06 21:08 3004

Dr Neal Shore joins Clarity's Clinical Advisory Board

SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2022-05-26 21:08 3053

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-s...

2022-03-28 21:06 2517

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-s...

2022-03-24 21:08 2604

First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-st...

2022-02-25 22:04 3807

US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer

SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2022-02-07 22:08 2826

Clarity advances to cohort 2 in the SARTATE™ neuroblastoma trial

SYDNEY, Feb. 1, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2022-02-01 21:58 2273

Clarity and Cardinal Health enter into Agreement for Targeted Copper Theranostics

SYDNEY, Dec. 2, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2021-12-02 21:58 2822

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-sta...

2021-12-01 21:57 2514

Fifty percent recruitment milestone for PROPELLER prostate cancer trial

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

* Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSM...

2021-11-10 22:06 2693

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials

SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australia...

2021-09-30 20:03 2110